NewsBenzingaInvivyd 和 SPEAR 研究组启动 FLINTLOCK II 期临床试验，评估高剂量单克隆抗体 VYD2311 在长新冠或疫苗接种后综合征患者中的安全性、耐受性、药代动力学和临床疗效 Invivyd 和 SPEAR 研究组启动 FLINTLOCK II 期临床试验，评估高剂量单克隆抗体 VYD2311 在长新冠或疫苗接种后综合征患者中的安全性、耐受性、药代动力学和临床疗效 Benzinga 2026.10.14 11:05 (GMT+0) Open on Benzinga Other news argenx Q3 EPS $7.80 Misses $7.83 Estimate, Sales $1.751B Beat $1.664B Estimate Nokia Q3 Adj. EPS $0.10 Beats $0.08 Estimate, Sales $5.931B Beat $5.800B Estimate Meta reaches deal with Zuckerberg: grants non-voting shares to address California wealth tax, in exchange for 8-year residency Advancements in DRAM, HBM and NAND Driving Technology Leadership in the AI Era eBay China launches large-scale personnel adjustment, with ratio possibly reaching 80% Kingstone: Less Reinsurance Means More Earnings And More Volatility (NASDAQ:KINS)
Meta reaches deal with Zuckerberg: grants non-voting shares to address California wealth tax, in exchange for 8-year residency
